Clinical trial

Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia

NCT00405171

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Nevirapine Normalized identity: nevirapineView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-06-01

PhasePHASE4

Conditions

HIV Infectionsunresolved

Hypercholesterolemiaunresolved

Antiretroviral Therapyunresolved

Interventions

NevirapineDRUG · verified · RxNorm: nevirapine

Sponsors & collaborators

University Hospital, Caenlead sponsor

Boehringer Ingelheimcollaborator

Mapped research locations

CaenFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00405171 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.